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Abstract
Background: Cryptosporidiosis represents a major public health problem. This infection has been reported worldwide as a
frequent cause of diarrhoea. Particularly, it remains a clinically significant opportunistic infection among immunocompromised
patients, causing potentially life-threatening diarrhoea in HIV-infected persons. However, the understanding about different
aspects of this infection such as invasion, transmission and pathogenesis is problematic. Additionally, it has been difficult to find
suitable animal models for propagation of this parasite. Efforts are needed to develop reproducible animal models allowing both
the routine passage of different species and approaching unclear aspects of Cryptosporidium  infection, especially in the
pathophysiology field.
Results: We developed a model using adult severe combined immunodeficiency (SCID) mice inoculated with Cryptosporidium
parvum or Cryptosporidium muris while treated or not with Dexamethasone (Dex) in order to investigate divergences in
prepatent period, oocyst shedding or clinical and histopathological manifestations. C. muris-infected mice showed high levels of
oocysts excretion, whatever the chemical immunosuppression status. Pre-patent periods were 11 days and 9.7 days in average
in Dex treated and untreated mice, respectively. Parasite infection was restricted to the stomach, and had a clear preferential
colonization for fundic area in both groups. Among C. parvum-infected mice, Dex-treated SCID mice became chronic shedders
with a prepatent period of 6.2 days in average. C. parvum-inoculated mice treated with Dex developed glandular cystic polyps
with areas of intraepithelial neoplasia, and also with the presence of intramucosal adenocarcinoma.
Conclusion: For the first time C. parvum is associated with the formation of polyps and adenocarcinoma lesions in the gut of
Dex-treated SCID mice. Additionally, we have developed a model to compare chronic muris and parvum cryptosporidiosis using
SCID mice treated with corticoids. This reproducible model has facilitated the evaluation of clinical signs, oocyst shedding,
location of the infection, pathogenicity, and histopathological changes in the gastrointestinal tract, indicating divergent effects of
Dex according to Cryptosporidium species causing infection.
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Background
Cryptosporidiosis represents a major public health prob-
lem. This infection, caused by protozoa of the genus Crypt-
osporidium, has been reported worldwide as a frequent
cause of diarrhoea, and its prevalence varies according to
different regions [1]. In developed countries, massive
Cryptosporidium  foodborne and waterborne outbreaks
have been reported. In developing countries, Cryptosporid-
ium affects mostly children under five [2]. Furthermore,
cryptosporidiosis remains a clinically significant oppor-
tunistic infection in immunocompromised patients, caus-
ing potentially life-threatening diarrhoea, especially in
those HIV-infected without access to highly active antiret-
roviral therapy (HAART) [3]. Additionally, these parasites
not only infect humans, but also cause morbidity in farm
animals, leading to economic losses [4]. Most Crypt-
osporidium species infect the epithelium of the gut but in
severe infections, dissemination can occur to extra-intesti-
nal sites [5]. Infection of the intestinal cells can result in
blunting of the intestinal villi, crypt hyperplasia and
inflammation. Epithelial cell apoptosis due to this para-
site has also been described [6,7].
Molecular techniques have been developed to differenti-
ate this parasite at the species and genotype levels, show-
ing that there are at least 16 different species [1], and
several methods have been used to study and characterize
different parasite strains. However, the understanding
about invasion, transmission, pathogenesis and epidemi-
ology is limited, and no effective drug against this infec-
tion is available. Previous studies based on multilocus
characterisation of Cryptosporidium isolates identified dif-
ferent sub-groups within some Cryptosporidium species [8-
11]. These groups exhibited different population genetic
structures (epidemic clonality and panmixia) that could
be correlated to defined phenotypes.
To contribute to the comprehension of the dynamics of
infection and to investigate biological divergence between
different populations of Cryptosporidium, tissue culture
and animal models have been used. It has been difficult
to find suitable models for cryptosporidiosis, as most
mammalians are susceptible to infection only as new-
borns [12]. However, some Cryptosporidium species can be
propagated in either chemically or genetically immuno-
suppressed mice. Particularly, adult mice with congenital
mutations such as nu/nu, scid, bg/nu, xid or mice with ster-
oid induced immunosuppression are susceptible to infec-
tion [12-17]. Efforts are still needed to develop
reproducible animal models allowing both the routine
passage of different species and approaching unclear
aspects of Cryptosporidium  infection, especially in the
pathophysiology field.
We have developed a model to compare chronic muris and
parvum cryptosporidiosis using SCID mice treated with
corticoids in order to evaluate clinical signs, location of
the infection, pathogenicity, oocyst shedding and his-
topathological changes in the gastrointestinal tract. This
model was chosen for the following reasons: i) Previous
studies have shown that host cell immunity during crypt-
osporidiosis is mediated by both Th1 and Th2 response
[18,19], thus SCID mice are more susceptible to the infec-
tion and to develop a chronic disease due to their defect
in T and B lymphocytes [20]. ii) It has been found that
during cryptosporidiosis there is an IFNγ mucosal
response with increased levels of Il15 [21]. IFNγ-induced
enterocyte resistance against C. parvum has been reported
[22]. Furthermore, glucocorticoids are known to have an
effect on the priming of the innate immune response [23],
and could suppress IFNγ-regulated gene expression [24].
Consequently, dexamethasone, a synthetic glucocorticos-
teroid, could be used to alter this innate immune
response. iii) This model of SCID mice treated with ster-
oids has been proven to be successful for the development
of Pneumocystis, another opportunistic agent [25].
Results
The pathological damage due to C. muris or C. parvum
infection was studied in SCID mice treated or not with
Dex. Main data related to infected mice included in the
study are shown in Table 1.
Dex induced a significant body weight loss in both Crypt-
osporidium infected and uninfected SCID mice (P < 0.001).
In contrast, no significant body weight change was associ-
ated with parasite infection. Once infected with C. muris,
mice from groups M and MDex became chronic shedders
and produced high numbers of oocysts without marked
differences between the groups. On the other hand, in ani-
mals inoculated with C. parvum, the oocyst excretion was
sporadic and limited in P mice, and high and chronic in
PDex mice, with a statistically significant difference (P =
0.002). Figure 1 shows the average of oocyst excretion in
different groups of mice. Analysis of variance showed that
the administration of Dex, Cryptosporidium species, and
the interaction of these factors significantly influenced
oocyst excretion (all the P < 0.001). The level of oocyst
excretion was higher in mice infected with C. muris than
in those infected with C. parvum.
Pre-patent period ranged from 6 to 11 days (9.7 days in
average) in M mice and it was 11 days for all MDex mice.
Geometric means of oocyst excretion before sacrifice were
1839 and 1159 oocysts/mg faeces respectively (Table 1).
At histological level, no difference between mice of groups
M or MDex was observed. C. muris localization was
restricted to the stomach, with no extra-gastric dissemina-
tion. Different stages of the parasite life cycle were present.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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Table 1: Experimental infection of Dexamethasone-treated or untreated SCID mice infected with C. parvum or C. muris: Main clinical 
and histopathological data
Groupa Mouse N° Day of euthanasia 
(post-infection)
Oocysts/mg faeces 
at euthanasia
Clinical manifestations Main histological changes
P 1 20 0 Occasional diarrhoea Undetected
2 28 0 Lethargy Undetected
3 28 1 None N.D.
4 84 1 Occasional diarrhoea Undetected
5 84 4 Occasional diarrhoea Undetected
6 84 0 Occasional diarrhoea N.D.
Pdex 7 20 29 Occasional diarrhoea Undetected
8 28 102 Lethargy, ruffled coat Undetected
9 28 95 Lethargy, ruffled coat N.D.
10 46 1182 Lethargy, ruffled coat Polyps with areas of low-grade and high-
grade intraepithelial neoplasia, and 
intramucosal adenocarcinoma at the 
ileocaecal region
11 62 240 Lethargy, ruffled coat Polyps with areas of low-grade and high-
grade intraepithelial neoplasia, and 
intramucosal adenocarcinoma at the 
ileocaecal region
12 84 695 Lethargy, ruffled coat Polyps with areas of low-grade and high-
grade intraepithelial neoplasia, and 
intramucosal adenocarcinoma at the 
ileocaecal region
M 13 20 1078 None Stomach heavily infected mainly at the 
fundic region; dilated glands; hyperplasia
14 20 407 None N.D.
15 28 742 None Stomach heavily infected mainly at the 
fundic glands, hyperplasia
16 84 4143 None Stomach heavily infected mainly at the 
fundic region; dilated glands; hyperplasia
17 84 4920 None Stomach heavily infected
18 84 5828 None None
Mdex 19 20 1538 Occasional diarrhoea Stomach heavily infected; dilated glands
20 20 166 Occasional diarrhoea N.D.
21 27 1241 Occasional diarrhoea N.D.
22 32 4155 Frequent diarrhoea, lethargy, 
ruffled coat
Stomach heavily infected mainly at the 
fundic glands; hyperplasia
23 46 900 Lethargy, ruffled coat Stomach heavily infected mainly at the 
fundic glands; hyperplasia
24 84 2051 None Stomach heavily infected mainly at the 
fundic glands; hyperplasia; a little 
inflammation
C 25 20 0 None Undetected
26 67 0 Lethargy, ruffled coat Undetected
27 84 0 None Undetected
Cdex 28 20 0 None Undetected
29 43 0 None Undetected
30 84 0 None Undetected
Cdex2 31 54 0 None Undetected
32 54 0 None Undetected
33 54 0 None Undetected
34 54 0 None Undetected
35 54 0 None Undetected
36 54 0 None Undetected
aExperimental groups were:
P: C. parvum-infected SCID mice; PDex: C. parvum-infected Dex-treated SCID mice; M: C. muris-infected SCID mice; MDex: C. muris-infected Dex-
treated SCID mice; C: Not infected SCID mice of control group inoculated with PBS; CDex: Not infected Dex-treated SCID mice of control group 
inoculated with PBS; CDex2: Not infected Dex-treated SCID mice that received an inoculum from which oocysts were previously removed by 
filtration; N.D.: Not done (These mice were not included in the histological examination).Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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Stomachs of all mice euthanatized at different dates, from
day 20 to day 84 post-infection, were heavily infected
mainly in fundic mucosae (Figure 2). Fundic gastric
glands were dilated and covered by a flattened epithelium.
Oxyntic cells were less numerous than in control mice and
preferentially visible in the deeper area. Fundic mucosa
was twice thinner than in control mice while pyloric
mucosa was similar to that in uninfected control mice. A
moderate inflammatory infiltrate, made of mononuclear
cells and neutrophile polynuclears, was observed in some
cases.
For C. parvum-infected SCID mice from group P, geomet-
ric mean of oocyst excretion before euthanasia was 1
oocyst/mg faeces. SCID mice from PDex group had a pre-
patent period ranging from 4 to 11 days (6.2 days in aver-
age) and developed a chronic infection. Geometric mean
of oocyst excretion before sacrifice was 195 oocysts/mg of
faeces for mice from group PDex. Two out of six PDex
SCID mice were severely ill and required euthanasia. In
mice infected with C. parvum, histopathological differ-
ences were revealed between Dex-treated and untreated
animals. Untreated SCID mice infected with C. parvum
have neither detectable parasites nor lesions at the histo-
logical level (Figure 3) at any time during the course of the
study.
In Dex-treated SCID mice infected with C. parvum, para-
site localization was restricted to the gastrointestinal tract,
mainly at the caecal region (Figure 3). Three out of five
(60%) histologically examined PDex SCID mice pre-
sented in the ileocaecal region polypoid, sessile, adenom-
atous masses, measuring approximately 2.5 mm in
diameter. They appeared as closely packed, branching
sometimes dilated tubular structures, separated by normal
or inflammatory lamina propria. Focal cystic dilation was
observed. Noticeably some tubules were covered by a low
grade or high grade dysplastic epithelium, which showed
mucin depletion and nuclear stratification. In some areas,
architectural distortion was associated with marked cellu-
lar atypias (Figure 4). Epithelial cells presented a loss of
their normal polarity. In addition, abnormal nuclear
changes consisting of prominent nucleoli and irregularly
scattered chromatin were observed (Figure 4). These
mucosal changes were suggestive of intraepithelial neo-
plasia of low or high grade. In some areas, major cellular
atypias, with foci of merged glands, typical of intramu-
cosal adenocarcinoma, invasive into lamina propria, were
found (Figures 4A and 4B).
Napierian logarithm of daily oocyst excretion (oocyst/mg faeces) in different groups of mice Figure 1
Napierian logarithm of daily oocyst excretion (oocyst/mg faeces) in different groups of mice. Experimental groups 
were: P: C. parvum-infected SCID mice; PDex: C. parvum-infected Dex-treated SCID mice; M: C. muris-infected SCID mice; 
MDex: C. muris-infected Dex-treated SCID mice. Each box represents the middle half of data, the white line being the median. 
Whiskers represent the extreme values within 1.5 times the box height.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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These major histological changes were earliest observed in
one mouse euthanatized at day 46 post-infection and
were found in all PDex mice necropsied after (Table 1).
They were always associated with the presence of C. par-
vum organisms (Figures 4 and 5). In contrast, no parasite
was detected in the stomach, duodenum, jejunum,
hepatic biliary system or pancreas. The possibility that
biotic (e.g. virus) or abiotic factors present in the inocu-
lum could be responsible for these lesions was discarded
by administering Dex-treated SCID mice with a filtered
inoculum (i.e. without Cryptosporidium  oocysts) (group
Cdex2). Neither parasites in the faeces or tissues nor
lesions were detected in these mice at any time of the
experience.
Discussion
We developed a new animal model that allows a good
propagation of two different species of Cryptosporidium. In
this study, adult SCID mice treated with Dex became
chronically infected with 105  C. parvum or  C. muris
oocysts, and had a significant oocyst shedding during all
the course of the experiments. Furthermore, this model
was useful to compare C. muris and C. parvum infections
at clinical, histopathological and parasitological levels.
In this study, variations in the expression of the disease in
terms of either Cryptosporidium species or Dex administra-
tion were shown. Amounts of oocysts discharged seemed
slightly lower in MDex than in M mice but this difference
was not statistically significant. However, it appeared that
the aggravation of the immunosuppression status did not
lead to an increase in the severity of C. muris infection.
Miller et al. previously reported that immunosuppressed
mice were as or less susceptible to C. muris than immuno-
competent mice [26]. However, this conclusion can
hardly be extrapolated to all Cryptosporidium species, as
long as in our experiments, the oocyst shedding was mark-
edly and significantly higher in PDex than in P group. Fur-
ther studies are required to determine minimal infectious
dose, ID50 (infectious dose to 50 percent of exposed indi-
viduals) and other data for each species and according to
the immunosuppression degree. Interestingly, data from
very recent experiments with C. parvum confirmed the
results of the present work (data not shown). The Dex-
treated SCID mouse model revealed therefore to be repro-
ducible.
C. muris infection caused damage to the gastric mucosa of
both mice from M and MDex groups. But though M mice
were less ill than MDex mice, there was no marked histo-
logical difference between them. Dilated, hypertrophied
and highly parasitized gastric glands without an extra gas-
tric dissemination of parasites were the main histopatho-
logical changes. Additionally, a little inflammatory
response was observed. Other authors have reported sim-
ilar findings in relation with C. muris gastric infection
[12,27,28]. However, to our knowledge, this is the first
report of a clear preferential localization of the parasite
colonization at the fundic level of the stomach, where acid
secreting glands are numerous [29]. This could suggest a
favourable influence of lower gastric pH on the growth of
C. muris.
Experimental Cryptosporidium muris infection of SCID mice Figure 2
Experimental Cryptosporidium muris infection of SCID mice. (A) Stomach section from a Dex-untreated SCID mouse 
euthanatized at day 84 post-infection; (B) Stomach section from a Dex-treated SCID mouse euthanatized at day 46 post-infec-
tion. In both cases, gastric glands are filled with numerous parasites at different developmental stages (arrows). No signs of 
inflammation. Hematoxylin & Eosin staining.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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On the other hand, several studies using animal models
have described histological changes in the intestinal epi-
thelium due to C. parvum infection, such as villous atro-
phy and crypt hyperplasia in the lower small intestine [13]
or in the caecum and the colon [12], cryptic hyperplasia
with abscesation of crypts in the large intestine [13], stunt-
ing and fusion of villi, replacement of enterocytes by
immature cells and eosinophilia of lamina propria [30],
small and large intestine mucosa severely damaged with
villous contraction and little or absent epithelial layer
[31]. Another report described an association between
Cryptosporidium sp. and aural-pharyngeal polyps in igua-
nas. These polyps were pedunculated masses composed of
glandular cystic structures lined by hyperplastic cuboidal
to columnar epithelium, containing numerous parasites
along the apical surfaces of the epithelial cells [32]. Nev-
ertheless, none of these studies have described the pres-
ence of carcinoma lesions associated to cryptosporidiosis.
These lesions were first observed unexpectedly after 46
days post-infection, when the infection had become
chronic, and were found only in C. parvum infected SCID
mice treated with Dex. These findings were recorded using
an inoculum relatively low (105 oocysts) in comparison
with the higher infectious doses, between 106 and 107,
used by others [12,33].
Several observations in our study suggest that combina-
tion of C. parvum with Dex administration is involved in
the generation of these significant histological changes.
Indeed, Dex seemed to be a critical factor to the develop-
Ileocaecal regions of mice from different groups Figure 3
Ileocaecal regions of mice from different groups. Normal caecum of (A) Uninfected mouse administered with dexame-
thasone (CDex group), (B) C. muris-infected Dex-treated mouse (MD group) and (C) C. parvum-infected mouse (P group). (D) 
Projection of polypoid structures with focal cystic dilation (arrows) developing inside the intestinal lumen of a C. parvum-
infected Dex-treated SCID mouse. Hematoxylin & Eosin staining.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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ment of intraepithelial adenocarcinoma in C. parvum-
infected SCID mice. Dex potentially alters the innate
immunity in C. parvum infected animals [23,24]. The
higher oocyst shedding found in mice presenting these
neoplasic lesions seems to confirm this assumption. Addi-
tionally, this kind of lesion was found neither in Dex-
untreated C parvum-infected animals with a low oocyst
excretion during the course of the study, nor in the control
Dex-treated non-infected group. A possible contamina-
tion of the inoculum with a virus or other agent poten-
tially responsible for these neoplasic lesions was also
discarded. Interestingly, C. muris was not able to induce
this type of epithelial changes and the reasons of this dif-
ferent expression of the disease are unclear. It has been
reported previously a variability in pathogenicity for dif-
ferent hosts between different Cryptosporidium species and
types, suggesting the existence of specific virulence factors
among species and isolates [34]. Further studies should be
done to clarify this difference in pathogenicity. It is impor-
tant to mention that these colonic neoplasic lesions are
not listed among the typical background diseases due to
the SCID mice genetic defect [35].
To our knowledge, this is the first time that C. parvum is
associated with cancerogenesis. There is one case report
that described cryptosporidiosis of the biliary tract clini-
cally mimicking a pancreatic cancer in an AIDS patient
[36]. However, biopsy of the gallbladder revealed crypt-
Experimental Cryptosporidium parvum infection of Dex-treated SCID mice: caecal region Figure 4
Experimental Cryptosporidium parvum infection of Dex-treated SCID mice: caecal region. (A) Polyp with areas of 
high-grade intraepithelial neoplasia (arrow 1) and intramucosal adenocarcinoma (arrow 2); (B) Abnormal nuclear changes con-
sisting of prominent nucleoli and irregularly scattered chromatin; (C) Highly irregular glands, areas of loss of glandular differen-
tiation. Presence of numerous parasites (arrow); (D) Presence of numerous parasites at different developmental stages in the 
intestinal epithelium (arrow). Hematoxylin & Eosin staining.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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osporidiosis causing inflammation of the biliary tract and
ruled out the diagnosis of neoplasia [36]. Furthermore, a
recent epidemiological study in Poland reported a high
frequency of cryptosporidiosis in patients with colorectal
cancer [37]. These data strengthen the interest of our
experimental observations.
Several infectious agents, including parasites, have been
linked to oncogenesis in humans. Some of these associa-
tions are strong. Particularly, Schistosoma hematobium has
been described as a definitive cause of urinary bladder
cancer by the International Agency for Research in Cancer.
Also, a proportion of cholangiocarcinoma of the liver
worldwide is attributable to Opisthorchiidae liver flukes
[38]. Other associations still speculative with some proto-
zoa were suggested on the basis of epidemiological obser-
vations, such as Trichomona vaginalis and cervical cancer,
or Toxoplasma gondii and tumors [39]. As well, a microbial
pathogen such as Helicobacter pylori has been classified as
oncogenic for humans due to its strong epidemiological
association with carcinoma of stomach and gastric lym-
phoma [38,40].
Because C. parvum is an opportunistic agent that causes
significant morbidity and mortality in immunocompro-
mised patients, it is possible that individuals infected with
this parasite may have a higher risk of developing colorec-
tal malignancies, especially when immunosuppression is
more severe. In a retrospective study that shows the inci-
dence and clinical course of colorectal malignancies in
HIV/AIDS patients, adenocarcinoma was the type of can-
cer most frequently found among them. These patients
Experimental Cryptosporidium parvum infection of Dex-treated SCID mice Figure 5
Experimental Cryptosporidium parvum infection of Dex-treated SCID mice. Low (A, D) and high magnification (B, C) 
of the caecal region showing the presence of abundant parasites (arrow), and high degree dysplasia (arrow). Hematoxylin & 
Eosin staining.Infectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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did not have familial antecedents of intestinal malignan-
cies or other risk factors, and developed tumors at earlier
ages in comparison to immunocompetent persons [41].
Unfortunately, no data about gastro-intestinal parasites in
these patients were given in the study [41]. More studies
have to be done in humans to evaluate cryptosporidiosis
as a possible risk factor of colorectal cancer.
Epidemiological studies have shown that environmental
factors may play a role in colon cancer susceptibility [42].
The association between chronic inflammation and can-
cer is also well known [43]. Particularly, colon cancer has
also been associated to inflammatory bowel disease. In
the latter case, cancer develops after sustained gut inflam-
mation. However, in the present work C. parvum infection
was associated with only mild inflammation of the intes-
tine as reported also by others [12].
Taking into consideration that the observations described
herein were replicated in a second experiment (unpub-
lished data), it can be concluded that C. parvum is able to
induce the formation of polyps and carcinogenic lesions
in the gut of Dex-treated SCID mice. However, more work
has to be done to elucidate this interesting association and
to further understand cryptosporidiosis pathogenesis.
Conclusion
In summary, for the first time C. parvum was associated
with the generation of polyps and in situ adenocarcinoma
in the gut of Dex-treated SCID mice. Additionally, we
have developed a model to compare chronic muris and
parvum cryptosporidiosis using SCID mice treated with
corticoids. This reproducible model has allowed the eval-
uation of clinical impact, oocyst shedding, location of the
infections, pathogenic power, and histopathological
changes indicating divergent effects of Dex according to
Cryptosporidium species.
Methods
Cryptosporidium oocysts
C. parvum IOWA and C. muris RN66 oocysts were pur-
chased from Waterborne™, Inc. (New Orleans, Louisiana)
and stored in shipping medium (Phosphate-buffered
saline (PBS) with penicillin, streptomycin, gentamycin,
amphotericin B and 0.01% Tween 20) at 4°C until use.
Oocyst viability before inoculation was determined by a
trypsin-taurocholate excystation test [44] and absence of
germs was assured by testing the oocyst suspensions on
Plate Count Agar and on Sabouraud plates.
Animals
Nine week-old male and female CB17-SCID mice were
obtained from a colony bred at the Pasteur Institute of
Lille (France), and maintained under aseptic conditions
in an isolator, with standard laboratory food for experi-
mental mice and water ad libitum. All cages, food, water
and bedding were sterilized before use. Faecal pellets were
collected from all mice before inoculation to ascertain the
absence of pre-existing Cryptosporidium infection. The con-
ditions for the care of laboratory animals stipulated in
European guidelines (Council directives on the protection
of animals for experimental and other scientific purposes.
J. Off. Communautés Européennes, 86/609/EEC, 1986,
December 18th, L358) were followed.
Immunosuppression
When needed (see the next section), SCID mice were
chemically immunosuppressed by administering 4 mg/L
of dexamethasone sodium phosphate (Dex) (Merck,
Lyon, France) via the drinking water. Immunosuppres-
sion was started two weeks prior to inoculation and was
maintained during the whole experimentation. Dex-
added water was replaced three times a week.
Experimental design
Twenty-four SCID mice, housed individually (one-
mouse-cage) in capped cages, were randomly divided into
four groups: P, M, PDex and MDex, described hereinafter.
Six SCID mice, housed by three, constituted two control
groups, C and CDex. Oral inoculation was done with 105
oocysts in 200 μl of PBS. Six mice were infected with C.
parvum oocysts (group P) and six others with C. muris
oocysts (group M). Under the effect of Dex immunosup-
pression, six mice were infected with C. parvum oocysts
(group PDex) and six others with C. muris oocysts (group
MDex). Mice of control groups were inoculated only with
PBS, without (group C) or with (group CDex) Dex admin-
istration. A further control group was constituted by six
SCID mice that received an inoculum from which oocysts
were previously removed by filtration with a Nanosep MF
tube with a 0.45 μm pore size membrane (group CDex2).
Quantification of the oocyst shedding
To evaluate the intensity of oocyst shedding over the
course of Cryptosporidium infection, freshly excreted faecal
pellets were collected three times a week from each mouse
and suspended in MilliQ water. Oocysts were detected
and numbered after staining faecal smears with modified
Ziehl-Neelsen stain [45].
Statistical analysis
Analyses of data were performed with the statistical soft-
ware S-PLUS 2000 (MathSoft, Seattle, WA, USA). For sta-
tistical analyse purposes, logarithmic transformations of
oocyst excretion values were used. Wilcoxon rank sum
tests were used to compare body weights or oocyst excre-
tion. An analysis of variance was conducted to account for
the effects of relevant factors and their interactions on
average daily excretion of oocysts. An average amount of
oocysts excreted per day was estimated for each mouseInfectious Agents and Cancer 2007, 2:22 http://www.infectagentscancer.com/content/2/1/22
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from all the unitary values, and was represented as a func-
tion of the mouse group in a Box & Whiskers Plot.
Histological examination
Periodically or when signs of imminent death appeared,
mice were euthanatized by a sodium pentobarbital (Ceva,
Libourne, France) intra-cardiac injection. The liver, stom-
ach and pancreas, a section of the duodenum, 3 sections
of the jejunum, the caecum, and 3 sections of the colon
were removed. Tissues were fixed in 10% neutral formalin
and embedded in paraffin. Histological sections were
stained with hematoxylin and eosin, and examined
microscopically for the detection of Cryptosporidium
organisms and/or histological modifications of the host
tissue. Pathological changes found in the mouse caecum
were classified according to the Vienna classification of
tumors of the digestive system [46,47].
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